Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2010 2
2011 2
2012 2
2013 3
2014 1
2015 5
2016 9
2017 17
2018 9
2019 11
2020 5
2021 8
2022 9
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
Cancer immunotherapy-associated hypophysitis.
Solinas C, Porcu M, De Silva P, Musi M, Aspeslagh S, Scartozzi M, Willard-Gallo K, Mariotti S, Saba L. Solinas C, et al. Among authors: aspeslagh s. Semin Oncol. 2018 Jun;45(3):181-186. doi: 10.1053/j.seminoncol.2018.09.002. Epub 2018 Oct 21. Semin Oncol. 2018. PMID: 30352754 Review.
Rationale for anti-OX40 cancer immunotherapy.
Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, Marabelle A. Aspeslagh S, et al. Eur J Cancer. 2016 Jan;52:50-66. doi: 10.1016/j.ejca.2015.08.021. Epub 2015 Nov 30. Eur J Cancer. 2016. PMID: 26645943 Review.
Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients.
Van Meerhaeghe T, Baurain JF, Bechter O, Orte Cano C, Del Marmol V, Devresse A, Doubel P, Hanssens M, Hellemans R, Lienard D, Rutten A, Sprangers B, Le Moine A, Aspeslagh S. Van Meerhaeghe T, et al. Among authors: aspeslagh s. Front Nephrol. 2022 Oct 31;2:1041819. doi: 10.3389/fneph.2022.1041819. eCollection 2022. Front Nephrol. 2022. PMID: 37675002 Free PMC article.
Immuno-oncology-101: overview of major concepts and translational perspectives.
Allard B, Aspeslagh S, Garaud S, Dupont FA, Solinas C, Kok M, Routy B, Sotiriou C, Stagg J, Buisseret L. Allard B, et al. Among authors: aspeslagh s. Semin Cancer Biol. 2018 Oct;52(Pt 2):1-11. doi: 10.1016/j.semcancer.2018.02.005. Epub 2018 Feb 8. Semin Cancer Biol. 2018. PMID: 29428479 Review.
Are phase I trials safe for older patients?
Baldini C, Le Saux O, Helissey C, Aspeslagh S, Castanon E, Varga A, Gazzah A, Bahleda R, Mir O, Massard C, Soria JC, Hollebecque A. Baldini C, et al. Among authors: aspeslagh s. J Geriatr Oncol. 2018 Mar;9(2):87-92. doi: 10.1016/j.jgo.2017.08.012. Epub 2017 Sep 8. J Geriatr Oncol. 2018. PMID: 28890328 Review.
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.
Gomez-Roca C, Cassier P, Zamarin D, Machiels JP, Perez Gracia JL, Stephen Hodi F, Taus A, Martinez Garcia M, Boni V, Eder JP, Hafez N, Sullivan R, Mcdermott D, Champiat S, Aspeslagh S, Terret C, Jegg AM, Jacob W, Cannarile MA, Ries C, Korski K, Michielin F, Christen R, Babitzki G, Watson C, Meneses-Lorente G, Weisser M, Rüttinger D, Delord JP, Marabelle A. Gomez-Roca C, et al. Among authors: aspeslagh s. J Immunother Cancer. 2022 May;10(5):e004076. doi: 10.1136/jitc-2021-004076. J Immunother Cancer. 2022. PMID: 35577503 Free PMC article. Clinical Trial.
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).
Postel-Vinay S, Lam VK, Ros W, Bauer TM, Hansen AR, Cho DC, Stephen Hodi F, Schellens JHM, Litton JK, Aspeslagh S, Autio KA, Opdam FL, McKean M, Somaiah N, Champiat S, Altan M, Spreafico A, Rahma O, Paul EM, Ahlers CM, Zhou H, Struemper H, Gorman SA, Watmuff M, Yablonski KM, Yanamandra N, Chisamore MJ, Schmidt EV, Hoos A, Marabelle A, Weber JS, Heymach JV. Postel-Vinay S, et al. Among authors: aspeslagh s. J Immunother Cancer. 2023 Mar;11(3):e005301. doi: 10.1136/jitc-2022-005301. J Immunother Cancer. 2023. PMID: 36927527 Free PMC article. Clinical Trial.
83 results